The investigation by Levi & Korsinsky into Atara Biotherapeutics for potential securities law violations is significant, as it follows a negative regulatory response from the FDA. The Complete Response Letter indicates issues with the EBVALLOTM application, which could lead to delays or additional costs. This legal and regulatory challenge is likely to negatively impact investor sentiment and the stock price in the short term.